Loading...

Daito PharmaceuticalLtd

DB:DPA
Snowflake Description

Flawless balance sheet and undervalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DPA
DB
¥36B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. The last earnings update was 66 days ago. More info.


Add to Portfolio Compare Print
DPA Share Price and Events
7 Day Returns
0.4%
DB:DPA
0.3%
DE Pharmaceuticals
1.8%
DE Market
1 Year Returns
-16.6%
DB:DPA
-13.6%
DE Pharmaceuticals
-8.9%
DE Market
DPA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Daito PharmaceuticalLtd (DPA) 0.4% 3% -5.9% -16.6% 5.6% 136.1%
DE Pharmaceuticals 0.3% 1.1% 5.4% -13.6% -11.5% 16.1%
DE Market 1.8% 2.7% 7.2% -8.9% 9.3% 11.7%
1 Year Return vs Industry and Market
  • DPA underperformed the Pharmaceuticals industry which returned -13.6% over the past year.
  • DPA underperformed the Market in Germany which returned -8.9% over the past year.
Price Volatility
DPA
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Daito PharmaceuticalLtd's competitors could be found in our database.

DPA Value

 Is Daito PharmaceuticalLtd undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Daito PharmaceuticalLtd to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data    Our intrinsic value calculation method has changed recently, learn more here.

Below are the data sources, inputs and calculation used to determine the intrinsic value for Daito PharmaceuticalLtd.

DB:DPA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:DPA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.74
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.737 (1 + (1- 30.86%) (20.34%))
0.893
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.89
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.893 * 5.96%)
5.55%

Discounted Cash Flow Calculation for DB:DPA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Daito PharmaceuticalLtd is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:DPA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (JPY, Millions) Source Present Value
Discounted (@ 5.55%)
2019 1,925.00 Analyst x1 1,823.74
2020 2,987.00 Analyst x1 2,681.01
2021 3,567.00 Analyst x1 3,033.18
2022 3,890.00 Analyst x1 3,133.84
2023 4,195.00 Analyst x1 3,201.77
2024 4,419.57 Est @ 5.35% 3,195.73
2025 4,588.21 Est @ 3.82% 3,143.15
2026 4,713.90 Est @ 2.74% 3,059.38
2027 4,807.51 Est @ 1.99% 2,956.01
2028 4,877.64 Est @ 1.46% 2,841.36
Present value of next 10 years cash flows ¥29,069.16
DB:DPA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ¥4,877.64 × (1 + 0.23%) ÷ (5.55% – 0.23%)
¥91,817.06
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ¥91,817.06 ÷ (1 + 5.55%)10
¥53,485.99
DB:DPA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ¥29,069.16 + ¥53,485.99
¥82,555.15
Equity Value per Share
(JPY)
= Total value / Shares Outstanding
= ¥82,555.15 / 12.51
¥50.62
DB:DPA Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:DPA represents 0.00767x of TSE:4577
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.00767x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (JPY) x Listing Adjustment Factor
= ¥ 6,597.14 x 0.00767
€50.62
Value per share (EUR) From above. €50.62
Current discount Discount to share price of €22.36
= -1 x (€22.36 - €50.62) / €50.62
55.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Daito PharmaceuticalLtd is available for.
Intrinsic value
>50%
Share price is €22.36 vs Future cash flow value of €50.62
Current Discount Checks
For Daito PharmaceuticalLtd to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Daito PharmaceuticalLtd's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Daito PharmaceuticalLtd's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Daito PharmaceuticalLtd's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Daito PharmaceuticalLtd's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:DPA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-11-30) in JPY ¥249.91
TSE:4577 Share Price ** TSE (2019-03-18) in JPY ¥2914
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 28.06x
Germany Market PE Ratio Median Figure of 423 Publicly-Listed Companies 19.52x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Daito PharmaceuticalLtd.

DB:DPA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:4577 Share Price ÷ EPS (both in JPY)

= 2914 ÷ 249.91

11.66x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Daito PharmaceuticalLtd is good value based on earnings compared to the DE Pharmaceuticals industry average.
  • Daito PharmaceuticalLtd is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Daito PharmaceuticalLtd's expected growth come at a high price?
Raw Data
DB:DPA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 11.66x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
10%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.8x
Germany Market PEG Ratio Median Figure of 275 Publicly-Listed Companies 1.42x

*Line of best fit is calculated by linear regression .

DB:DPA PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 11.66x ÷ 10%

1.16x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Daito PharmaceuticalLtd is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Daito PharmaceuticalLtd's assets?
Raw Data
DB:DPA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-11-30) in JPY ¥2,359.48
TSE:4577 Share Price * TSE (2019-03-18) in JPY ¥2914
Germany Pharmaceuticals Industry PB Ratio Median Figure of 10 Publicly-Listed Pharmaceuticals Companies 2.37x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.76x
DB:DPA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:4577 Share Price ÷ Book Value per Share (both in JPY)

= 2914 ÷ 2,359.48

1.24x

* Primary Listing of Daito PharmaceuticalLtd.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Daito PharmaceuticalLtd is good value based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Daito PharmaceuticalLtd's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Daito PharmaceuticalLtd has a total score of 5/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

DPA Future Performance

 How is Daito PharmaceuticalLtd expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Daito PharmaceuticalLtd expected to grow at an attractive rate?
  • Daito PharmaceuticalLtd's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Daito PharmaceuticalLtd's earnings growth is positive but not above the Germany market average.
  • Daito PharmaceuticalLtd's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:DPA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:DPA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 10%
DB:DPA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 5.5%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 19.3%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:DPA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:DPA Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-05-31
2022-05-31
2021-05-31 45,400 6,535 4,000 1
2020-05-31 43,400 5,943 3,700 1
2019-05-31 41,000 5,913 3,300 1
DB:DPA Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2018-11-30 39,566 5,829 3,127
2018-08-31 39,933 3,147
2018-05-31 39,875 5,465 3,041
2018-02-28 39,701 2,913
2017-11-30 39,219 4,539 2,820
2017-08-31 38,554 2,658
2017-05-31 37,984 5,069 2,656
2017-02-28 37,283 2,698
2016-11-30 37,270 3,385 2,722
2016-08-31 36,747 2,559
2016-05-31 36,370 2,948 2,566
2016-02-29 36,416 2,639

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Daito PharmaceuticalLtd's earnings are expected to grow by 10% yearly, however this is not considered high growth (20% yearly).
  • Daito PharmaceuticalLtd's revenue is expected to grow by 5.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:DPA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Daito PharmaceuticalLtd Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DPA Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-05-31
2022-05-31
2021-05-31 319.60 319.60 319.60 1.00
2020-05-31 295.70 295.70 295.70 1.00
2019-05-31 263.70 263.70 263.70 1.00
DB:DPA Past Financials Data
Date (Data in JPY Millions) EPS *
2018-11-30 249.91
2018-08-31 251.50
2018-05-31 243.03
2018-02-28 232.78
2017-11-30 225.35
2017-08-31 212.40
2017-05-31 212.24
2017-02-28 215.60
2016-11-30 217.52
2016-08-31 204.49
2016-05-31 205.05
2016-02-29 210.87

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Daito PharmaceuticalLtd is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Daito PharmaceuticalLtd's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Daito PharmaceuticalLtd has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

DPA Past Performance

  How has Daito PharmaceuticalLtd performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Daito PharmaceuticalLtd's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Daito PharmaceuticalLtd's year on year earnings growth rate has been positive over the past 5 years.
  • Daito PharmaceuticalLtd's 1-year earnings growth is less than its 5-year average (10.9% vs 11%)
  • Daito PharmaceuticalLtd's earnings growth has not exceeded the DE Pharmaceuticals industry average in the past year (10.9% vs 22%).
Earnings and Revenue History
Daito PharmaceuticalLtd's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Daito PharmaceuticalLtd Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DPA Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-11-30 39,566.00 3,127.00 2,405.00 1,522.00
2018-08-31 39,933.00 3,147.00 2,246.00 1,522.00
2018-05-31 39,875.00 3,041.00 2,301.00 1,522.00
2018-02-28 39,701.00 2,913.00 2,554.00 1,266.00
2017-11-30 39,219.00 2,820.00 2,414.00 1,266.00
2017-08-31 38,554.00 2,658.00 2,542.00 1,266.00
2017-05-31 37,984.00 2,656.00 2,394.00 1,266.00
2017-02-28 37,283.00 2,698.00 2,523.00 1,174.00
2016-11-30 37,270.00 2,722.00 2,438.00 1,174.00
2016-08-31 36,747.00 2,559.00 2,282.00 1,174.00
2016-05-31 36,370.00 2,566.00 2,348.00 1,174.00
2016-02-29 36,416.00 2,639.00 2,107.00 1,182.00
2015-11-30 35,691.00 2,403.00 2,358.00 1,182.00
2015-08-31 35,370.00 2,468.00 2,353.00 1,182.00
2015-05-31 34,058.00 2,246.00 2,243.00 1,182.00
2015-02-28 33,765.00 2,080.00 2,531.00 890.00
2014-11-30 32,528.00 2,010.00 2,168.00 890.00
2014-08-31 31,560.00 1,864.00 2,033.00 890.00
2014-05-31 31,196.00 1,811.00 2,029.00 890.00
2014-02-28 29,876.00 1,910.00 1,751.00 1,113.00
2013-11-30 29,680.00 1,787.00 1,871.00 1,113.00
2013-08-31 29,050.00 1,799.00 1,923.00 1,113.00
2013-05-31 28,956.00 1,786.00 1,988.00 1,113.00
2013-02-28 28,551.00 1,429.00 2,190.00 1,035.00
2012-11-30 28,002.00 1,429.00 2,185.00 1,035.00
2012-08-31 27,709.00 1,475.00 2,075.00 1,035.00
2012-05-31 27,151.00 1,389.00 1,878.00 1,035.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Daito PharmaceuticalLtd has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Daito PharmaceuticalLtd used its assets less efficiently than the DE Pharmaceuticals industry average last year based on Return on Assets.
  • Daito PharmaceuticalLtd's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Daito PharmaceuticalLtd's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Daito PharmaceuticalLtd has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

DPA Health

 How is Daito PharmaceuticalLtd's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Daito PharmaceuticalLtd's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Daito PharmaceuticalLtd is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Daito PharmaceuticalLtd's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Daito PharmaceuticalLtd's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 3.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Daito PharmaceuticalLtd Company Filings, last reported 3 months ago.

DB:DPA Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-11-30 29,952.00 7,417.00 1,769.00
2018-08-31 29,064.00 9,447.00 1,605.00
2018-05-31 28,495.00 7,435.00 1,711.00
2018-02-28 27,929.00 9,027.00 1,657.00
2017-11-30 27,326.00 9,203.00 1,711.00
2017-08-31 26,309.00 10,158.00 1,632.00
2017-05-31 25,813.00 9,142.00 1,617.00
2017-02-28 25,241.00 10,236.00 1,839.00
2016-11-30 24,472.00 9,646.00 1,622.00
2016-08-31 23,637.00 10,018.00 1,459.00
2016-05-31 23,558.00 10,461.00 1,351.00
2016-02-29 23,191.00 10,418.00 1,890.00
2015-11-30 22,977.00 8,565.00 1,589.00
2015-08-31 22,564.00 9,794.00 1,611.00
2015-05-31 21,854.00 9,556.00 1,918.00
2015-02-28 20,886.00 9,174.00 2,780.00
2014-11-30 20,255.00 9,582.00 3,648.00
2014-08-31 19,401.00 10,893.00 4,557.00
2014-05-31 16,624.00 11,272.00 2,513.00
2014-02-28 16,209.00 10,103.00 2,009.00
2013-11-30 15,786.00 10,611.00 2,792.00
2013-08-31 15,178.00 10,592.00 2,778.00
2013-05-31 15,072.00 12,729.00 4,149.00
2013-02-28 14,081.00 12,506.00 3,816.00
2012-11-30 12,525.00 12,035.00 2,607.00
2012-08-31 11,711.00 12,421.00 2,662.00
2012-05-31 11,516.00 11,729.00 1,572.00
  • Daito PharmaceuticalLtd's level of debt (24.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (67.2% vs 24.8% today).
  • Debt is well covered by operating cash flow (78.6%, greater than 20% of total debt).
  • Daito PharmaceuticalLtd earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Daito PharmaceuticalLtd's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Daito PharmaceuticalLtd has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

DPA Dividends

 What is Daito PharmaceuticalLtd's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.24%
Current annual income from Daito PharmaceuticalLtd dividends. Estimated to be 1.37% next year.
If you bought €2,000 of Daito PharmaceuticalLtd shares you are expected to receive €25 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Daito PharmaceuticalLtd's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.5%).
  • Daito PharmaceuticalLtd's dividend is below the markets top 25% of dividend payers in Germany (3.89%).
Upcoming dividend payment

Purchase Daito PharmaceuticalLtd on or before the 'Buy Limit' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:DPA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 331 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:DPA Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
2023-05-31
2022-05-31
2021-05-31 44.00 1.00
2020-05-31 40.00 1.00
2019-05-31 36.00 1.00
DB:DPA Past Annualized Dividends Data
Date (Data in ¥) Dividend per share (annual) Avg. Yield (%)
2019-01-11 36.000 1.252
2018-08-30 36.000 1.092
2018-07-13 36.000 1.080
2018-04-13 36.000 1.008
2018-01-12 30.000 0.836
2017-08-30 30.000 1.010
2017-07-11 30.000 1.066
2017-04-14 30.000 1.278
2017-01-13 30.000 1.311
2016-08-26 30.000 1.363
2016-07-12 30.000 1.299
2016-04-13 30.000 1.059
2016-04-12 30.000 0.925
2016-01-12 30.000 1.083
2016-01-08 30.000 0.995
2015-08-26 30.000 1.027
2015-07-10 30.000 0.983
2015-04-14 27.273 1.087
2015-04-10 27.273 1.131
2015-01-14 27.273 1.196
2015-01-09 27.273 1.541
2014-08-29 27.273 1.556
2014-07-10 27.273 1.635
2013-08-30 27.273 2.007
2013-07-09 27.273 2.099
2013-04-09 22.727 1.867
2012-08-29 22.727 1.845
2012-07-10 22.727 2.313
2012-01-13 22.727 2.217
2011-10-12 18.182 1.656
2011-08-29 18.182 1.441
2011-07-12 18.182 1.454
2011-04-07 18.182 1.423
2011-01-07 18.182 1.831
2010-08-27 13.636 2.035
2010-07-13 13.636 1.671
2010-04-07 13.636 1.046
2010-03-24 13.636 0.977

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Daito PharmaceuticalLtd has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Daito PharmaceuticalLtd only paid a dividend in the past 9 years.
Current Payout to shareholders
What portion of Daito PharmaceuticalLtd's earnings are paid to the shareholders as a dividend.
  • Dividends paid are thoroughly covered by earnings (6.9x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Daito PharmaceuticalLtd's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Daito PharmaceuticalLtd afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Daito PharmaceuticalLtd has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

DPA Management

 What is the CEO of Daito PharmaceuticalLtd's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yasunobu Otsuga
AGE 68
CEO Bio

Mr. Yasunobu Otsuga has been the President of Daito Pharmaceutical Co., Ltd. since August 2012 and serves as its Chief Executive Officer. Mr. Otsuga Joined Daito Pharmaceutical Co., Ltd. In March 1975. Mr. Otsuga served as Vice President and Managing Director of Daito Pharmaceutical Co., Ltd. since August 2011 and July 1993 respectively and also served as its Chief of Business Planning Office. April 1973. Mr. Otsuga Joined Nichi-iko Pharmaceutical Co., Ltd. Mr. Otsuga served as Manager of Operations Planning Department at since Jun 1984. Mr. Otsuga has been a Representative Director of Daito Pharmaceutical Co., Ltd. since August 2007. .

CEO Compensation
  • Insufficient data for Yasunobu to compare compensation growth.
  • Insufficient data for Yasunobu to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Yasunobu Otsuga

TITLE
CEO, President & Representative Director
AGE
68

Masuo Nomura

TITLE
Executive Officer

Mitsuo Hirono

TITLE
Managing Executive Officer & GM of Administrative Division

Junichi Kikuta

TITLE
Senior MD & Director
AGE
68
TENURE
8.6 yrs

Hideyuki Kato

TITLE
VP & Director
AGE
71

Tatsuo Shinohara

TITLE
Executive Officer & GM of Pharmaceutical Division

Kiyotaka Kido

TITLE
Executive Officer & GM of Production Division

Hisao Takahashi

TITLE
Executive Officer & GM of Reliability Assurance Division

Hiroshi Kubota

TITLE
Executive Officer and GM of Research & Development Division

Shinya Oka

TITLE
Executive Officer
Board of Directors Tenure

Average tenure and age of the Daito PharmaceuticalLtd board of directors in years:

5.1
Average Tenure
68
Average Age
  • The tenure for the Daito PharmaceuticalLtd board of directors is about average.
Board of Directors

Yasunobu Otsuga

TITLE
CEO, President & Representative Director
AGE
68
TENURE
11.6 yrs

Junichi Kikuta

TITLE
Senior MD & Director
AGE
68
TENURE
6.6 yrs

Hideyuki Kato

TITLE
VP & Director
AGE
71
TENURE
17.5 yrs

Michio Tsuda

TITLE
Director
AGE
70
TENURE
3.6 yrs

Hitoshi Hori

TITLE
External Director
AGE
65
TENURE
3.6 yrs

Ichizo Yamamoto

TITLE
External Director
AGE
62
TENURE
3.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Daito PharmaceuticalLtd's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Daito PharmaceuticalLtd has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

DPA News

Simply Wall St News

DPA Company Info

Description

Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. The company offers various active pharmaceutical ingredients and intermediates, prescription drugs, OTC drugs, and home-delivery medicines; formulations in various forms, such as tablets, capsules, troches, granules, and powders; and contract manufacturing services for formulations of medicinal products to pharmaceutical companies. It also sells health food products. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was founded in 1942 and is headquartered in Toyama, Japan.

Details
Name: Daito Pharmaceutical Co.,Ltd.
DPA
Exchange: DB
Founded: 1942
¥288,930,678
12,513,773
Website: http://www.daitonet.co.jp
Address: Daito Pharmaceutical Co.,Ltd.
326, Yokamachi,
Toyama,
Toyama, 939-8567,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 4577 Common Shares The Tokyo Stock Exchange JP JPY 24. Mar 2010
DB DPA Common Shares Deutsche Boerse AG DE EUR 24. Mar 2010
Number of employees
Current staff
Staff numbers
734
Daito PharmaceuticalLtd employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/18 21:16
End of day share price update: 2019/03/18 00:00
Last estimates confirmation: 2019/02/26
Last earnings filing: 2019/01/11
Last earnings reported: 2018/11/30
Last annual earnings reported: 2018/05/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.